Sushmita Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sushmita Das has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Afruja Khan
Department of Biological Sciences Indian Institute of Science Education and Research Kolkata Mohanpur 741246 India
1 shared publication - Amirul Islam Mallick
Indian Institute of Science Education and Research Kolkata
1 shared publication - Pradip Kumar Tarafdar
Indian Institute of Science Education and Research Kolkata
1 shared publication - Subhadeep Gupta
Department of Biological Sciences, Indian Institute of Science Education and Research (IISER) Kolkata, Mohanpur, West Bengal 741246, India
1 shared publication - Subrata Das
Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, Nadia, West Bengal, 741246, India, iiserkol.ac.in
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Biomaterials
- Vol. 2025 (1)
Bacterial Extracellular Vesicles (BEVs) Derived From Lactococcus lactis as Multimodal Drug Delivery Platforms
Advances in drug delivery technologies involve the extracellular vesicles as a promising bioactive drug delivery vehicle expected to improve targeted therapeutic delivery in pharmaceutical innovations. Recently, Gram‐negative bacterial extracellular vesicles (outer membrane vesicles or OMVs) have gained attention for their role in host–microbe interactions and potential in drug delivery. Bacterial extracellular vesicle (BEV) shedding is a conserved mechanism of intra‐ and interspecies communication, providing critical insights into host–microbe interactions. However, the biogenesis and compositional diversity of BEVs produced by Gram‐positive bacteria remain underexplored. Understanding the translational application potential of BEVs remains elusive due to the suboptimal isolation of BEVs and limited structural–functional characterization. A comprehensive study to develop BEVs as delivery vehicles will provide critical insights into the perspective of microbial–host interplay and illuminate the modulation of the drug delivery strategy. Here, using a food‐grade probiotic Lactococcus lacti s subsp. cremoris MG1363 (strain NZ9000), we demonstrated that perturbing peptidoglycan biosynthesis with ampicillin, which targets penicillin‐binding proteins (PBPs), significantly enhances BEV production. We further explored the interaction between BEVs and host cells through this optimized BEV biogenesis, revealing its cargo‐delivering capability. Furthermore, to understand the potential of BEVs as a multimodal drug delivery platform, we target multidrug‐resistant microbial pathogens and cancer cell proliferation with drug‐encapsulated BEVs. With a generally recognized as safe (GRAS) recognition of L. lactis, we demonstrated that drug‐loaded L. lactis BEVs can offer recognizable therapeutic effects. These findings highlight the versatile nature of L. lactis BEVs as stable, safe, natural nanocarriers capable of personalized cargo delivery with broad therapeutic applications.
- 1 January 2025
- Published by Wiley in International Journal of Biomaterials
- Vol. 2025 (1)
Open AccessBacterial Extracellular Vesicles (BEVs) Derived From Lactococcus lactis as Multimodal Drug Delivery Platforms
Advances in drug delivery technologies involve the extracellular vesicles as a promising bioactive drug delivery vehicle expected to improve targeted therapeutic delivery in pharmaceutical innovations. Recently, Gram‐negative bacterial extracellular vesicles (outer membrane vesicles or OMVs) have gained attention for their role in host–microbe interactions and potential in drug delivery. Bacterial extracellular vesicle (BEV) shedding is a conserved mechanism of intra‐ and interspecies communication, providing critical insights into host–microbe interactions. However, the biogenesis and compositional diversity of BEVs produced by Gram‐positive bacteria remain underexplored. Understanding the translational application potential of BEVs remains elusive due to the suboptimal isolation of BEVs and limited structural–functional characterization. A comprehensive study to develop BEVs as delivery vehicles will provide critical insights into the perspective of microbial–host interplay and illuminate the modulation of the drug delivery strategy. Here, using a food‐grade probiotic Lactococcus lacti s subsp. cremoris MG1363 (strain NZ9000), we demonstrated that perturbing peptidoglycan biosynthesis with ampicillin, which targets penicillin‐binding proteins (PBPs), significantly enhances BEV production. We further explored the interaction between BEVs and host cells through this optimized BEV biogenesis, revealing its cargo‐delivering capability. Furthermore, to understand the potential of BEVs as a multimodal drug delivery platform, we target multidrug‐resistant microbial pathogens and cancer cell proliferation with drug‐encapsulated BEVs. With a generally recognized as safe (GRAS) recognition of L. lactis, we demonstrated that drug‐loaded L. lactis BEVs can offer recognizable therapeutic effects. These findings highlight the versatile nature of L. lactis BEVs as stable, safe, natural nanocarriers capable of personalized cargo delivery with broad therapeutic applications.